PlainRecalls
FDA Drug Low Class III Terminated

Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05), b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India For BluePoint Laboratories

Reported: November 23, 2016 Initiated: October 27, 2016 #D-0137-2017

Product Description

Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05), b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India For BluePoint Laboratories

Reason for Recall

Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.

Details

Units Affected
a) 15,409 bottles b) 5,128 bottles
Distribution
Nationwide and Puerto Rico
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05), b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India For BluePoint Laboratories. Recalled by Amerisource Health Services. Units affected: a) 15,409 bottles b) 5,128 bottles.
Why was this product recalled?
Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 23, 2016. Severity: Low. Recall number: D-0137-2017.